Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B.

Pharmacol Biochem Behav. 2010 Jun;95(4):449-56. doi: 10.1016/j.pbb.2010.03.006. Epub 2010 Mar 25.

2.

Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats.

Quisenberry AJ, Baker LE.

Psychopharmacology (Berl). 2015 Dec;232(24):4411-9. doi: 10.1007/s00213-015-4065-0. Epub 2015 Sep 15.

PMID:
26374456
3.

Combined effects of modafinil and d-amphetamine in male Sprague-Dawley rats trained to discriminate d-amphetamine.

Quisenberry AJ, Prisinzano T, Baker LE.

Pharmacol Biochem Behav. 2013 Sep;110:208-15. doi: 10.1016/j.pbb.2013.07.011. Epub 2013 Jul 21.

PMID:
23880213
4.

Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study.

Wuo-Silva R, Fukushiro DF, Borçoi AR, Fernandes HA, Procópio-Souza R, Hollais AW, Santos R, Ribeiro LT, Corrêa JM, Talhati F, Saito LP, Aramini TC, Kameda SR, Bittencourt LR, Tufik S, Frussa-Filho R.

Addict Biol. 2011 Oct;16(4):565-79. doi: 10.1111/j.1369-1600.2011.00341.x. Epub 2011 Jul 25.

PMID:
21790900
5.

Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants.

Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK.

Eur J Pharmacol. 2007 Jul 30;568(1-3):112-23. Epub 2007 Apr 5.

PMID:
17477916
6.

The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors.

Schmitt KC, Reith ME.

PLoS One. 2011;6(10):e25790. doi: 10.1371/journal.pone.0025790. Epub 2011 Oct 17. Erratum in: PLoS One. 2012;7(1): doi.10.1371/annotation/ba711a7c-13fb-4d18-89a8-28dcc68fcd04..

7.

Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction.

Shuman T, Cai DJ, Sage JR, Anagnostaras SG.

Behav Brain Res. 2012 Dec 1;235(2):105-12. doi: 10.1016/j.bbr.2012.07.039. Epub 2012 Aug 3.

8.

R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.

Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, Tanda G, Newman AH.

Biol Psychiatry. 2012 Sep 1;72(5):405-13. doi: 10.1016/j.biopsych.2012.03.022. Epub 2012 Apr 25.

9.

Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.

Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH.

J Pharmacol Exp Ther. 2009 May;329(2):738-46. doi: 10.1124/jpet.108.146142. Epub 2009 Feb 5.

10.

Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil.

Gold LH, Balster RL.

Psychopharmacology (Berl). 1996 Aug;126(4):286-92.

PMID:
8878344
11.

Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley PM, Lecomte JM, Schwartz JC.

Br J Pharmacol. 2013 Jun;169(3):632-44. doi: 10.1111/bph.12149.

12.

Dopaminergic role in stimulant-induced wakefulness.

Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM.

J Neurosci. 2001 Mar 1;21(5):1787-94.

13.

Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats.

Ishizuka T, Murakami M, Yamatodani A.

Eur J Pharmacol. 2008 Jan 14;578(2-3):209-15. Epub 2007 Sep 26.

PMID:
17920581
14.

Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation.

Federici M, Latagliata EC, Rizzo FR, Ledonne A, Gu HH, Romigi A, Nisticò R, Puglisi-Allegra S, Mercuri NB.

Neuroscience. 2013 Nov 12;252:118-24. doi: 10.1016/j.neuroscience.2013.07.071. Epub 2013 Aug 8.

PMID:
23933217
15.

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Caldarone BJ, Paterson NE, Zhou J, Brunner D, Kozikowski AP, Westphal KG, Korte-Bouws GA, Prins J, Korte SM, Olivier B, Ghavami A.

J Pharmacol Exp Ther. 2010 Dec;335(3):762-70. doi: 10.1124/jpet.110.174011. Epub 2010 Sep 23.

16.
17.

Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.

Mitchell HA, Bogenpohl JW, Liles LC, Epstein MP, Bozyczko-Coyne D, Williams M, Weinshenker D.

Pharmacol Biochem Behav. 2008 Dec;91(2):217-22. doi: 10.1016/j.pbb.2008.07.014. Epub 2008 Jul 25. Erratum in: Pharmacol Biochem Behav. 2009 Mar;92(1):197.

18.

Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.

Broderick PA, Hope O, Okonji C, Rahni DN, Zhou Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):157-71.

PMID:
14687870
19.

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine.

Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC.

Neuroscience. 1998 Dec;87(4):905-11.

PMID:
9759978
20.

Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat.

Wisor JP, Dement WC, Aimone L, Williams M, Bozyczko-Coyne D.

Pharmacol Biochem Behav. 2006 Nov;85(3):492-9. Epub 2006 Nov 28.

PMID:
17134745

Supplemental Content

Support Center